CIK 0001595097 · Non-accelerated filer<br>Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464348039
- Phone
- 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +47,564 | $21.47 | $1.0M | 2,349,231 |
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +25,769 | $22.23 | $573K | 2,375,000 |
| 2024-08-16 | Kung Winston Director | Grant or award | +5,566 | 5,566 | ||
| 2024-08-16 | Kung Winston Director | Grant or award · Stock options (right to buy) | +5,566 | 5,566 | ||
| 2024-06-18 | Moran Sean F. Chief Financial Officer | Option exercise 10b5-1 | +1,958 | $30.00 | $59K | 50,563 |
| 2024-06-18 | Moran Sean F. Chief Financial Officer | Sale 10b5-1 | −1,958 | $42.12 | $82K | 48,605 |
| 2024-06-18 | Moran Sean F. Chief Financial Officer | Option exercise · Options to purchase common stock 10b5-1 | −1,958 | 0 | ||
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise 10b5-1 | +11,667 | $30.00 | $350K | 96,067 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −11,667 | $42.24 | $493K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise 10b5-1 | +1,770 | $14.10 | $25K | 86,170 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −1,770 | $42.24 | $75K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise 10b5-1 | +2,322 | $4.26 | $10K | 86,722 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −2,322 | $42.24 | $98K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −7,179 | $42.24 | $303K | 77,221 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise · Options to purchase common stock 10b5-1 | −11,667 | 0 | ||
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise · Options to purchase common stock 10b5-1 | −1,770 | 31,057 | ||
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Option exercise · Options to purchase common stock 10b5-1 | −2,322 | 49,739 | ||
| 2024-06-17 | Moran Sean F. Chief Financial Officer | Option exercise 10b5-1 | +6,730 | $14.10 | $95K | 55,335 |
| 2024-06-17 | Moran Sean F. Chief Financial Officer | Sale 10b5-1 | −6,730 | $46.77 | $315K | 48,605 |
| 2024-06-17 | Moran Sean F. Chief Financial Officer | Option exercise · Options to purchase common stock 10b5-1 | −6,730 | 11,217 |
Page 5 of 10 · 200 trades